Loading...

BVX

BVX

ABIVAX SA

(ABVX)

2026 6-K

Financial Report

22 May '26

Shareholder Meeting Results

20 May '26

Royalty Buyback Agreement

7 May '26

Preparatory Documents

20 Apr '26

Abivax Results

23 Mar '26

Clinical Efficacy Report

23 Feb '26

Financial Update

15 Dec '25

Financial Update

8 Sep '25

Public Offering Announcement

24 Jul '25

Positive Trial Results

22 Jul '25

Shareholder Meeting Results

11 Jun '25

Q1 2025 Filing

2 Jun '25

Trial Enrollment Complete

29 Apr '25

Board Appointment

22 Apr '25

Financial Results Announced

24 Mar '25

Corporate Disclosure

10 Jan '25

Board Resignation

23 Dec '24

Equity Offering Announcement

19 Nov '24

Key Financial Update

14 Nov '24

Filing Announcement

3 Oct '24

Press Release Issued

3 Oct '24

Filing Report

26 Sep '24

Press Release Issued

25 Sep '24

Filing Announcement

9 Sep '24

Financial Results Update

9 Sep '24

Regulatory Filing Update

6 Aug '24

Filing Update

16 Jul '24

Shareholder Meeting Results

4 Jun '24

Press Release Issued

7 May '24

Company Filing Notice

2 Apr '24

February Filing

2 Feb '24

Filing Summary

22 Jan '24

External Links:

SEC

On February 21, 2026, Abivax S.A. announced evidence of anti-fibrotic activity for Obefazimod and new clinical efficacy and safety analyses in inflammatory bowel disease, highlighting advancements in their treatment options.

AI Assistant

ABIVAX SA

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.